Full-Time

Senior AI Scientist

Updated on 8/8/2026

Owkin

Owkin

201-500 employees

AI-powered diagnostics and drug development

No salary listed

Remote in UK + 2 more

More locations: Remote in Germany | Paris, France

Remote

PhD

Category
Biology & Biotech (1)
Required Skills
LLM
Python
React.js
Git
Machine Learning
REST APIs

Get referred to Owkin

See people who can refer or advise you

Requirements
  • Demonstrated expertise in agentic artificial intelligence, including large language model reasoning such as Chain-of-Thought and ReAct, long-context management, and tool-augmented generation.
  • Expert-level Python skills and the ability to write clean, modular code that interfaces with complex application programming interfaces and databases.
  • A PhD in Computer Science, Machine Learning, or Applied Mathematics, or equivalent high-level industry experience.
  • Ability to explain complex agent behaviors to both artificial intelligence peers and biological experts.
  • Fluency in English.
Responsibilities
  • Design and implement sophisticated artificial intelligence agents capable of multi-step reasoning, tool use, and self-correction.
  • Develop frameworks in which agents propose hypotheses and design optimal experiments for validation in a wet lab.
  • Rapidly prototype and iterate on agentic architectures, moving from research papers to production-grade code.
  • Maintain awareness of frontier generative artificial intelligence and agentic workflows.
  • Publish high-impact research at the intersection of artificial intelligence, biology, and chemistry.
Desired Qualifications
  • French language skills.
  • Computational Biology or Chemistry expertise.
  • Deep understanding of the central dogma data stack, from processing raw sequencing and omics data to interpreting the physics and geometry of macromolecular structures.
  • Experience with Active Learning, Bayesian Optimization, or Optimal Experimental Design.
  • Experience training and deploying large-scale models or managing complex multi-agent orchestrations.
  • Experience understanding response to treatment or causal discovery in biological systems.
  • A proven track record of taking a research concept and turning it into a functional tool used by other scientists.
  • Contributions to top-tier journals or machine learning conferences such as NeurIPS, ICML, or ICLR, or equivalent online content such as GitHub projects or patents.

Owkin uses artificial intelligence to improve medical diagnostics and speed up the development of new drugs, specifically within the field of oncology. The company builds machine learning models that analyze diverse patient data, such as tissue samples and genetic records, to help researchers predict how patients will respond to specific treatments during clinical trials. Unlike many competitors, Owkin utilizes a collaborative network of academic centers and pharmaceutical companies to train its AI on vast, diverse datasets while maintaining strict data privacy. Their goal is to advance precision medicine by making the drug discovery process faster, less expensive, and more accurate for patients.

Company Size

201-500

Company Stage

Late Stage VC

Total Funding

$368M

Headquarters

Paris, France

Founded

2016

Get referred to Owkin

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • Sanofi expanded its partnership June 2026 into a five-year K Pro license.
  • AstraZeneca signed a three-year K Pro deal in May 2026 for drug-development agents.
  • Waiv raised $33 million in March 2026, separating diagnostics and preserving cash for AI agents.

What critics are saying

  • Sifted reported August 2025 layoffs of dozens, signaling cost pressure and morale damage.
  • Sanofi and AstraZeneca can switch vendors after their 2026 K Pro licenses expire.
  • Owkin's BASI pitch remains unproven; a failed INVOKE trial would undermine the core thesis.

What makes Owkin unique

  • K Pro fuses multimodal patient data, pathology, genomics, and reasoning agents for pharma.
  • Owkin's 800-hospital network gives proprietary training data competitors can't easily replicate.
  • Anthropic's Claude integration makes Pathology Explorer an externally usable biology agent.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Flexible Work Hours

Remote Work Options

Growth & Insights and Company News

Headcount

6 month growth

-8%

1 year growth

-5%

2 year growth

-3%
Giant Health
Jun 20th, 2026
Owkin, Sanofi expand AI collaboration to build drug development AI agents.

Owkin, Sanofi expand AI collaboration to build drug development AI agents. Posted: 20 june 2026 Owkin and Sanofi are expanding their artificial intelligence collaboration through a multi-year agreement to co-develop AI-enabled biopharma agents for drug research and development. Posted: 22 june 2026 Healthcare innovation continues to evolve at an extraordinary pace - driven by advances in AI, digital health, virtual care, and new models of medical education. At the centre of many of these conversations is Prof. Shafi Ahmed, its Chairman and... Posted: 19 june 2026 The trial marks the first time a vaccine whose active ingredient was entirely designed by AI has been tested in humans, researchers at the University of Cambridge in the U.K. The experimental jab is intended to be a "universal vaccine"...

UrduPoint
Jun 17th, 2026
Cleveland Clinic Abu Dhabi collaborates with Owkin to launch world's first clinical AI scientist.

Cleveland Clinic Abu Dhabi collaborates with Owkin to launch world's first clinical AI scientist. Faizan Hashmi Published June 17, 2026 | 02:30 PM ABU DHABI, (UrduPoint / Pakistan Point News / WAM - 17th Jun, 2026) Cleveland Clinic Abu Dhabi today announced a collaboration with Owkin to launch 'Aila,' the world's first clinical artificial intelligence scientist. The advanced AI platform is designed to support real-time clinical decision-making and accelerate medical research using real patient data. 'Aila' is designed to reason across complex datasets, generate actionable medical insights, and continuously learn. It transforms how clinicians interact with data - enabling faster, more informed, and more precise decision-making at the point of care. 'Aila' is designed to function as a clinical AI scientist, unlocking and connecting datasets. Through a secure, intuitive natural-language interface, physicians will be able to query vast amounts of clinical data in real time and receive insights that previously required days or weeks of manual analysis. The platform is expected to transform fragmented information into a unified, queryable knowledge layer that delivers meaningful insights at the critical moment when clinical decisions are made. "This collaboration reflects our commitment to innovation and our responsibility to actively create the future of healthcare," said Dr. Georges-Pascal Haber, Chief Executive Officer of Cleveland Clinic Abu Dhabi. "By responsibly harnessing advanced AI built on real patient data, we are empowering our caregivers with powerful tools that enhance clinical judgment, advance discovery, and ultimately improve outcomes for the patients and communities we serve." The initial deployment of 'Aila' will focus on prostate cancer, integrating multiple clinical data sources including electronic health records, physician notes, pathology reports, and medical imaging. Supported by the UAE's AI-enabled infrastructure and built on Owkin's agentic K Pro - purpose-built for biology platform, 'Aila' is engineered to scale across additional medical specialities and increasingly complex data modalities. Over time, the platform is designed to incorporate advanced data types such as multi-omics and genomic data, supporting large-scale precision medicine initiatives. Facebook Twitter Reddit Pinterest Whatsapp

World Pharma Today
Jun 9th, 2026
Sanofi and owkin partner to co-develop agentic AI tools for drug discovery.

Sanofi and owkin partner to co-develop agentic AI tools for drug discovery. Note* - All images used are for editorial and illustrative purposes only and may not originate from the original news provider or associated company. - Never miss a story with notifications - Browse free from any location or device. Media Packs Expand Your Reach With Its Customized Solutions Empowering Your Campaigns To Maximize Your Reach & Drive Real Results! - Book a Conference Call

AllSci
Jun 8th, 2026
Sanofi expands Owkin partnership for purpose-built AI agents.

Sanofi expands Owkin partnership for purpose-built AI agents. June 8, 2026 Sanofi has signed a multi-year collaboration agreement with Owkin, the Franco-American agentic AI company, to co-develop bespoke AI agents deployed through K Pro, Owkin's AI Scientist platform - extending a partnership that dates to 2021 and now covers Sanofi's full pharmaceutical value chain. The arrangement includes a five-year license for K Pro and positions Owkin as the end-to-end builder of purpose-built agents integrated into Sanofi's existing agentic AI workflows. Financial terms were not disclosed. The collaboration builds on a prior EUR 90 million (approximately USD 104 million) strategic partnership initiated in 2021, which focused on target identification across four oncology programs and was later expanded to include drug positioning for Sanofi's immunology pipeline. The current agreement represents a structural shift: where earlier work was program-specific, the K Pro license is platform-wide, designed to operate across Sanofi's entire R\&D continuum from early discovery through clinical development. K Pro is described by Owkin as an agentic AI platform built on multimodal biological data - including genomics, histopathology imaging, and clinical outcomes - combined with what the company calls biological reasoning models. Central to the architecture is Owkin Zero, a 32-billion parameter model trained on approximately 10 million curated biomedical question-and-answer pairs, designed to execute mechanistic scientific reasoning rather than general text retrieval. Proprietary histology foundation models, including H0 and iBOT, trained on more than 200,000 pathologist annotations, provide a spatial tissue-level reasoning layer. Under the Sanofi arrangement, Owkin will develop AI agents that autonomously perform complex tasks - competitive intelligence, landscape forecasting, target evaluation, and clinical decision support - deployed within Sanofi's internal governance and security frameworks. The scope is deliberately enterprise-wide rather than indication-specific. Owkin previously entered a three-year license agreement with AstraZeneca for K Pro in May 2026, where initial capabilities focused on competitive intelligence for specific targets and assets. The Sanofi arrangement appears broader, covering co-development of novel agents across multiple workflow categories rather than a single defined use case. Industry and transaction context. The deal reflects a pattern among large pharma companies of sourcing AI platform capabilities through time-limited licensing arrangements with a vendor-led build component, rather than through acquisitions or equity stakes. The AstraZeneca K Pro deal, announced three weeks prior, followed the same structural logic - a defined term, Owkin-led agent development, and deployment within the pharma's own IT environment. Two major pharma companies licensing the same platform within weeks of each other is notable for a privately held AI vendor and suggests Owkin is actively converting its prior pharma relationships into recurring platform revenue. Sanofi's AI partnering behavior has been consistent across modalities. In January 2026, Sanofi extended its collaboration with CytoReason for AI-powered computational disease modeling in a deal valued at up to USD 16 million - its third expansion of that relationship. The CytoReason deal is structured around proprietary disease models and evidence graphs rather than agentic workflow execution, illustrating that Sanofi is layering multiple AI vendors with distinct technical approaches rather than consolidating on a single platform. The K Pro collaboration occupies a different functional layer: autonomous agent execution across the R\&D value chain rather than disease-specific predictive modeling. Sanofi's broader AI vendor portfolio also includes a worldwide exclusive license with Earendil Labs for AI-discovered bispecific antibodies in autoimmune disease, announced in April 2025 with USD 125 million upfront and up to USD 1.72 billion in milestones. That deal follows traditional biopharma licensing economics tied to specific molecules. The K Pro arrangement sits in a structurally different category - platform access rather than asset acquisition - and the two approaches are complementary rather than substitutive within Sanofi's AI sourcing strategy. This article was generated with AI assistance and reviewed and edited by the AllSci editorial team Explore more at AllSci News: https://allsci.com/news/

Business Wire
Jun 5th, 2026
Owkin and Sanofi expand partnership with five-year AI agent collaboration backed by K Pro licence

Owkin has announced a multi-year collaboration with Sanofi to co-develop next-generation biopharma agents, backed by a five-year licence for K Pro, Owkin's AI scientist platform. The partnership will focus on creating AI-driven agents designed to autonomously perform complex tasks throughout drug research and development. The companies have collaborated since 2021 through a €90 million strategic partnership focused on oncology target identification and patient subgrouping. Owkin will lead the end-to-end development of AI agents deployed through K Pro, which combines multimodal patient data with specialised biological AI systems to support pharmaceutical workflows from early discovery through clinical development. The collaboration aims to embed agentic AI systems into Sanofi's existing workflows, enabling faster and more precise decision-making across the drug development lifecycle.